-220/126 CK 1813

PATENT

1813

Attorney Docket No. 3495.0008-09

Group Art Unit:

Examiner: J. Parkin

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Serial No.: 08/466,921

Filed: June 6, 1995

For: "METHOD OF PRODUCING

ANTIBODIES TO ANTIGENS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)"

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$220.00 as specified by Section 1.17(p).

Copies of the listed documents were previously submitted in serial no. 08/052,727, filing date April 27, 1993 (now abandoned), upon which applicants rely for the benefits provided in 35 U.S.C. § 120.

070 WJ 07/01/96 08466921

220.00 CK

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L. L. P. 1300 I STREET, N. W. WASHINGTON, DC. 20005

202-408-4000

LAW OFFICES

1 126

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration of relevant portions thereof by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents constitutes "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

By:

David J. Kulik

Registration No. 36,576

Dated: June 24, 1996

Finnegan, Henderson, Farabow, Garrett & Dunner, L. L. P.

1300 I STREET, N. W. WASHINGTON, DC 20005 202-408-4000 In re Application of:

(Natt Application of:

For: METHOD OF PRODUCING ANTIBODIES TO ANTIGENS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

- Enclosed is an Information Disclosure Statement. The item(s) checked below are appropriate:
- [], Applicants hereby petition for a ___ month extension of time to respond to the above Office Action. The fee of \$__ for the Extension is enclosed.

The claims are calculated below:

Claims Remaining		esent Additional
After Amendment	Previously Paid E	xtra Rate Fee
Total	-	0 x \$ 22 \$
Indep.	-	0 x \$ 78
[X] First Presentation of Multiple Dep. Claim(s) + \$250		
Subtotal \$		
Reduction by ½ if small entity -		
		TOTAL \$

- [X] A fee of \$220.00 to cover the cost of the Information Disclosure Statement fee under 37 C.F.R. § 1.17(p) is enclosed.
- [X] A check for \$220.00 to cover the above fee is enclosed.

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Date: June 24, 1996

By:

David J. Kulik

Registration No. 36,576

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

1300 I Street, N.W.

Washington, D.C. 20005-3315

(202) 408-4000